Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Doctor of Philosophy, King's College London
Award Date: 1 May 2009
Medicine, Bachelor of Medicine, University of Bristol
Award Date: 1 Aug 2007
Cellular and Molecular Pathology, Bachelor of Science, University of Bristol
Award Date: 1 Aug 2004
Fingerprint
Dive into the research topics where Piers Patten is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., & 12 others, 25 Jan 2024, In: New England Journal of Medicine. 390, 4, p. 326-337 12 p.Research output: Contribution to journal › Article › peer-review
36 Citations (Scopus) -
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update
Dreyling, M., Fowler, N. H., Dickinson, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Patten, P. EM., Thieblemont, C. & Schuster, S. J., 25 Apr 2024, In: Blood. 143, 17, p. 1713-1725 13 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile13 Citations (Scopus)67 Downloads (Pure) -
Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy
Woo, T., Carter, M., Follows, G. & Patten, P. E. M., 2023, In: Frontiers in oncology. 13, 1260003.Research output: Contribution to journal › Article › peer-review
Open Access -
Chronic lymphocytic leukemia therapy guided by measurable residual disease
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Patten, P. & Hillmen, P., 10 Dec 2023, In: New England Journal of Medicine.Research output: Contribution to journal › Article › peer-review
Open AccessFile51 Downloads (Pure) -
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., & 12 others, May 2023, In: The Lancet Oncology. 24, 5, p. 535-552 18 p.Research output: Contribution to journal › Article › peer-review
Open Access36 Citations (Scopus)
-
Identifying the most dangerous cells in B cell chronic lymphocytic leukaemia
Hoogeboom, R., Karimi, M. M. & Patten, P.
1/05/2022 → 31/10/2024
Project: Research
-
-
Understanding SARS-Cov-2 variant evolution in haemato-oncology patients
LLS Leukemia & Lymphoma Society
1/09/2021 → 31/08/2024
Project: Research
-
Immune efficacy of COVID-19 vaccines for patients with myelodysplastic syndromes (MDS)
4/05/2021 → 3/10/2022
Project: Research